September is World Alzheimer's Month and this year’s theme is “Time to act on dementia, time to act on Alzheimer’s." ...

Alzheimer’s disease is a progressive neurodegenerative disorder that is characterized by declining mental abilities that affect memory, cognitive function, and personality. It is the most common cause ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

In Alzheimer’s disease (AD), significant numbers of nerve cells in the brain die, affecting patients’ ability to remember things and to think clearly — resulting in confusion, behavioral changes and ...

While Alzheimer’s disease (AD) has no cure, five prescription medicines have been approved by the U.S. Food and Drug Administration (FDA) to treat disease symptoms that impact thinking and memory.

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining mental abilities that affect a person’s memory, cognition, and personality. It is the most common cause of ...

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

Alzheimer’s disease is the most common type of dementia among older people. Its exact cause remains unknown, but may stem from a combination of environmental factors, lifestyle and genetics. Alzheimer ...

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...